Drugs / Phenprocoumon
Phenprocoumon
also known as
Marcumar · BS-7565 · Fencumar · Fenprocumon · Liquamar · Marcoumar · Phenprocoumarol · Phenprocoumarole · +3 more
Small molecule targets VKORC1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | LIQUAMAR | — | 1957-12-30 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
1956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02066662 | Jul 2013 → Mar 2020 | arterial disorder | RWTH Aachen University | Completed | No outcome recorded |
| Phase 4 | NCT00528671 | Jan 2006 → Nov 2013 | cardiac valvular defect | Heart and Diabetes Center North-Rhine Westfalia | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 18 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01849666 Comparator | Sep 2013 → Apr 2014 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02256683 Comparator | Jul 2014 → May 2018 | atrial fibrillation | Johannes Gutenberg University Mainz | Terminated | No outcome recorded |
| Phase 2 | NCT02872649 Comparator | Jan 2013 → Jun 2015 | hemorrhagic disease, thrombotic disease | Daniel Zimpfer, MD | Terminated | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT02933697 Comparator | Jun 2017 → Jul 2022 | atrial fibrillation, end stage renal failure | Atrial Fibrillation Network | Completed | No outcome recorded |
| Phase 3 | NCT02942576 Comparator | Mar 2017 → Sep 2018 | atrial fibrillation | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT02046460 Comparator | Sep 2013 → Jun 2019 | cervical artery dissection | Stefan Engelter | Completed | No outcome recorded |
| Phase 3 | NCT01674647 Comparator | Oct 2012 → Jan 2014 | atrial fibrillation | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01164046 Comparator | Aug 2010 → Jul 2014 | neoplasm, venous thromboembolism | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 3 | NCT00895505 Comparator | Feb 2008 → Feb 2012 | venous thromboembolism | University Hospital, Bonn | Unknown | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT04437303 Comparator | Nov 2020 → Mar 2024 | aortic valve stenosis, hemorrhagic disease, myocardial infarction, stroke disorder +2 | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03463317 Comparator | Feb 2018 → Nov 2024 | atrial fibrillation | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT02723981 Background | Apr 2016 → May 2018 | ST-elevation myocardial infarction, intermediate coronary syndrome | IHF GmbH - Institut für Herzinfarktforschung | Withdrawn | No outcome recorded |
| Phase 4 | NCT02591225 Comparator | Oct 2015 → Dec 2017 | atrial fibrillation | University of Ulm | Unknown | No outcome recorded |
| Phase 4 | NCT02227550 Comparator | Dec 2014 → Apr 2017 | atrial fibrillation | Atrial Fibrillation Network | Completed | No outcome recorded |
| Phase 4 | NCT01812200 Comparator | Oct 2012 → May 2013 | acute coronary syndrome, atrial fibrillation | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01352702 Comparator | May 2011 → May 2014 | acute coronary syndrome, atherosclerosis, atrial fibrillation, coronary artery disorder | German Heart Center Munich | Terminated | No outcome recorded |
| Phase 4 | NCT01339819 Comparator | Apr 2011 → May 2012 | atrial fibrillation | German Heart Center Munich | Completed | No outcome recorded |
| Phase 4 | NCT00586287 Comparator | Jan 2007 → Dec 2011 | atrial fibrillation, pulmonary embolism | Cantonal Hospital of St. Gallen | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | phenprocoumon | “the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards” NCT01674647 ↗17“For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.” NCT04437303 ↗ “Phenprocoumon” NCT02942576 ↗ “phenprocoumon” NCT01164046 ↗ |
| Known as | BS-7565 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | Fencumar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | Fenprocumon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | Liquamar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | Marcoumar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | Marcumar | “Plavix, Marcumar, Xarelto, Pradaxa” NCT02723981 ↗ |
| Known as | Phenprocoumarol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | Phenprocoumarole | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | Phenprocoumone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | Phenprocumone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Known as | RO-1-4849 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1465 ↗ |
| Action | Inhibit | “Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor” CHEMBL1465 ↗1“vitamin K antagonist (VKA) Phenprocoumon” NCT02591225 ↗ |
| Modality | Small molecule | — CHEMBL1465 ↗ |
| Route | Oral | “need for oral anticoagulation for a two-week treatment with either dabigatran or phenprocoumon” NCT01339819 ↗ |
| Target | VKORC1 | “Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor” CHEMBL1465 ↗ |